BOOSTING ONCOLOGY RESEARCH WITH INTEGRATED KRAS ASSAY PROVIDERS AND RAS ASSAYS

In the promptly evolving area of oncology analysis, precise and effective mutation screening is very important for building qualified therapies. The KRAS companies Platform performs a pivotal position With this landscape by presenting extensive methods for KRAS mutation profiling and Investigation. KRAS mutations, located in somewhere around 95% of